(United States Federal Circuit) - In an appeal of inter partes review of the claims of a pharaceutical patent for anticipation by prior art, the Patent Trial and Appeal Board's decision that the prior art did not anticipate the patent's claims by a preponderance of the evidence is affirmed where substantial evidence supports the Board's finding that the prior art does not disclose the claimed treatment regimen with sufficient clarity to satisfy the demanding standard for anticipation.
Source: findlaw.com